GlassScriptPhysician profile
Mark S Shimko
NPI 1457541278
$5,417.39
in general payments reported to CMS, 2019-2025
32 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $482 · 2021: $473 · 2022: $896 · 2023: $923 · 2024: $969 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.14 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $751.76 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $739.30 | 2019-2025 | Erleada, Akeega |
| Teleflex LLC | $523.13 | 2021-2025 | Urolift, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $498.63 | 2021-2025 | |
| Abbvie INC. | $337.17 | 2020-2025 | Botox |
| Astellas Pharma US INC | $328.19 | 2019-2025 | Xtandi |
| Urogen Pharma, INC. | $295.58 | 2021-2025 | Jelmyto |
| Progenics Pharmaceuticals, INC. | $184.20 | 2022-2025 | Pylarify |
| Merck Sharp & Dohme LLC | $159.15 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $159.08 | 2019-2025 | |
| Immunitybio, INC. | $135.17 | 2025 | |
| Myriad Genetic Laboratories, INC. | $134.60 | 2023-2025 | Prolaris |
| Allergan, INC. | $117.35 | 2019-2022 | |
| Boston Scientific Corporation | $114.38 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, Ams 700 |
| Olympus America INC. | $111.08 | 2023-2024 | Itind System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.31 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $86.67 | 2023-2024 | Gemtesa, Orgovyx |
| Novartis Pharmaceuticals Corporation | $86.38 | 2023-2025 | |
| Neotract INC. | $84.63 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $69.00 | 2019-2022 | |
| 180 Medical, INC. | $60.60 | 2021-2022 | |
| Accord Healthcare, INC. | $48.60 | 2023-2024 | |
| Coloplast Corp | $48.51 | 2023-2024 | Porges Coloplast |
| Endo USA, INC. | $48.31 | 2024-2025 | Aveed, Xiaflex |
| Urovant Sciences INC | $43.12 | 2021 | |
| Ferring Pharmaceuticals INC. | $39.46 | 2019 | |
| Medtronic, INC. | $30.02 | 2023 | Interstim |
| Myovant Sciences INC. | $29.69 | 2021-2022 | |
| Photocure INC | $14.65 | 2021 | |
| Foundation Medicine, INC. | $14.63 | 2021 | |
| Endo Pharmaceuticals INC. | $13.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shimko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.